DelveInsight's“ Essential Tremor Pipeline Insight 2025” report provides comprehensive insights about 7+ companies and 10+ pipeline drugs in the Essential Tremor pipeline landscape. It covers the Essential Tremor Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Essential Tremor Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Essential Tremor Pipeline? Click here to explore the therapies and trials making headlines @ Essential Tremor Pipeline Outlook Report

Key Takeaways from the Essential Tremor Pipeline Report

• In July 2025, Jazz Pharmaceuticals conducted a study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.
• DelveInsight's Essential Tremor Pipeline report depicts a robust space with 7+ active players working to develop 10+ pipeline therapies for Essential Tremor treatment.
• The leading Essential Tremor Companies such as Merz Pharma, SAGE Therapeutics, GE Healthcare, Praxis Precision Medicines, OB Pharmaceuticals, Novartis, Jazz Pharmaceuticals and others.
• Promising Essential Tremor Therapies such as SAGE-324, CAD-1883, NBI-827104, JZP385, CX-8998, SAGE-217, Memantine, Pregabalin, and others.

Want to know which companies are leading innovation in Essential Tremor? Dive into the full pipeline insights @ Essential Tremor Clinical Trials Assessment

The Essential Tremor Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Essential Tremor Pipeline Report also highlights the unmet needs with respect to the Essential Tremor.

Essential Tremor Overview

Essential tremor (ET) is a chronic, progressive neurologic disease. The hallmark motor feature of ET is a 4–12-Hz kinetic tremor (i.e., a tremor that occurs during voluntary movements such as writing or eating) that involves the hands and arms, but which may also eventually spread to involve the head (i.e., neck), voice, jaw, and other body regions. Given the presence of etiologic, clinical, pharmacologic response profile and pathologic heterogeneity, there is increasing support for the notion that ET may be a family of diseases whose central defining feature is kinetic tremor of the arms, and which might more appropriately be referred to as“the essential tremors.

Essential Tremor Emerging Drugs Profile

• SAGE-324: Sage therapeutics

SAGE-324 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). NAS GABAA receptor PAMs bind to both synaptic and extrasynaptic GABAA receptors, enhancing inhibitory activity of the GABAergic system, the major inhibitory neurotransmission system in the brain. GABA is the primary inhibitory neurotransmitter in the central nervous system and plays a critical role in maintaining balanced neuronal activity in the brain. GABA dysregulation has been implicated in the pathophysiology of ET. It is currently being evaluated in Phase II stage of development.

If you're tracking ongoing Essential Tremor Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Essential Tremor Treatment Drugs

The Essential Tremor Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Essential Tremor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Essential Tremor Treatment.
• Essential Tremor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Essential Tremor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Essential Tremor market.

Essential Tremor Companies

Merz Pharma, SAGE Therapeutics, GE Healthcare, Praxis Precision Medicines, OB Pharmaceuticals, Novartis, Jazz Pharmaceuticals and others.

Essential Tremor Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Essential Tremor Products have been categorized under various Molecule types such as,

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

From emerging drug candidates to competitive intelligence, the Essential Tremor Pipeline Report covers it all – check it out now @ Essential Tremor Market Drivers and Barriers, and Future Perspectives

Scope of the Essential Tremor Pipeline Report

• Coverage- Global
• Essential Tremor Companies- Merz Pharma, SAGE Therapeutics, GE Healthcare, Praxis Precision Medicines, OB Pharmaceuticals, Novartis, Jazz Pharmaceuticals and others.
• Essential Tremor Therapies- SAGE-324, CAD-1883, NBI-827104, JZP385, CX-8998, SAGE-217, Memantine, Pregabalin, and others.
• Essential Tremor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Essential Tremor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what's next for the Essential Tremor Treatment landscape in this detailed analysis @ Essential Tremor Emerging Drugs and Major Players

Table of Contents